Hikma Pharmaceuticals PLC reiterated earnings guidance for the year 2024. For the year, expected Group revenue to grow in the range of 4% to 6% and for core operating profit to be in the range of $660 million to $700 million in 2024, in line with prior guidance.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,976 GBX | +0.82% | +2.70% | +10.45% |
May. 03 | Deutsche Bank Starts Hikma Pharmaceuticals Coverage at Buy | MT |
May. 03 | Jefferies cuts AJ Bell; Deutsche likes ConvaTec | AN |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.45% | 5.47B | |
+31.52% | 690B | |
+24.80% | 546B | |
-5.21% | 358B | |
+17.02% | 323B | |
+5.01% | 287B | |
+14.06% | 235B | |
+5.51% | 199B | |
-9.82% | 195B | |
+3.98% | 161B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Hikma Pharmaceuticals plc Reiterates Earnings Guidance for the Year 2024